Administration of teriparatide for four years cyclically compared to two years daily in treatment Naïve and alendronate treated women

We evaluated if equivalent doses of TPTD given cyclically over 4-years could increase BMD >2-years of daily TPTD in 2 cohorts of women; previously untreated (Rx-Naïve) and women previously treated with ALN (ALN-Rx). In Rx-Naïve, women were randomized to daily TPTD for 24 months (Daily; n = 23) or...

Full description

Saved in:
Bibliographic Details
Published in:Bone (New York, N.Y.) N.Y.), 2019-03, Vol.120, p.246-253
Main Authors: Cosman, Felicia, Nieves, Jeri W., Roimisher, Catherine, Neubort, Simon, McMahon, Donald J., Dempster, David W., Lindsay, Robert
Format: Article
Language:English
Subjects:
Absorptiometry, Photon
Alendronate
Alendronate - administration & dosage
Alendronate - adverse effects
Alendronate - pharmacology
Alendronate - therapeutic use
Anabolic
Antiresorptive
Biomarkers - metabolism
Bone Density - drug effects
Bone Remodeling - drug effects
Cohort Studies
Combination therapy
Cyclic therapy
Drug Administration Schedule
Drug Therapy, Combination
Female
Fractures, Bone - drug therapy
Humans
Middle Aged
Teriparatide
Teriparatide - administration & dosage
Teriparatide - adverse effects
Teriparatide - pharmacology
Teriparatide - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We evaluated if equivalent doses of TPTD given cyclically over 4-years could increase BMD >2-years of daily TPTD in 2 cohorts of women; previously untreated (Rx-Naïve) and women previously treated with ALN (ALN-Rx). In Rx-Naïve, women were randomized to daily TPTD for 24 months (Daily; n = 23) or cyclic TPTD for 48 months (3 months on, 3 months off; Cyclic; n = 25). In ALN-Rx, women were randomized to continued ALN plus daily TPTD for 24 months, followed by ALN alone for 24 months (Daily; n = 21) or TPTD for 48 months (3 months on, 3 months off) while ALN was continued (Cyclic; n = 20). BMD (DXA) was measured at spine (LS), total hip (TH) and femoral neck (FN). The primary analysis compared 4 years of cyclic therapy to 2 years of daily therapy in RX-naïve and ALN-RX cohorts. In Rx-Naïve, BMD changes at 24 months after Daily TPTD vs. 48 months after Cyclic TPTD were: LS 8.6% vs. 6.9%; TH 2.5% vs. 2.6%, and FN 1.6% vs. 2.2%. None of the BMD changes differed significantly between groups but all changes were significant over time within each group (p 
ISSN:8756-3282
1873-2763
DOI:10.1016/j.bone.2018.10.020